Sanofi
About Sanofi
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Market cap
- $107.8B
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $107.8B
- Dividend yield
- 5.51%
- Shares outstanding
- 2.5B
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 1, 2002
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Trading 20% below its 52-week high.
- Pays a dividend yielding about 5.51% annually.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Sanofi.
Write a review
News about Sanofi
News & sentiment via Polygon.io
